Genasense

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1999-2009
0519992009

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
OBJECTIVES Merkel cell carcinoma (MCC) is a rare, aggressive neuroendocrine malignancy of the skin. Preclinical studies have… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
2007
2007
973 criterion in the GM301 trial3 of Genasense plus dacarbazine versus dacarbazine alone in advanced melanoma because it is the… (More)
  • figure 1
Is this relevant?
2006
2006
PURPOSE To assess the feasibility and antitumor activity of oblimersen sodium, an antisense oligonucleotide directed to the Bcl-2… (More)
Is this relevant?
2004
2004
PURPOSE To assess the feasibility of administering oblimersen sodium, a phosphorothioate antisense oligonucleotide directed to… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • table 4
Is this relevant?
2004
2004
New strategies have evolved in the treatment of patients with non-Hodgkin's lymphoma (NHL). Anti-sense oligonucleotides (ASO) and… (More)
Is this relevant?
2003
2003
PURPOSE The near-universal emergence of imatinib resistance in patients with acute forms of Philadelphia chromosome-positive… (More)
  • figure 2
  • figure 1
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2003
2003
Overexpression of Bcl-2 is a potential mechanism for chemoresistance in acute leukemia and has been associated with unfavorable… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
2001
Highly Cited
2001
PURPOSE Bcl-2 is a negative prognostic indicator in prostate cancer, implicated in the development of androgen independence and… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Is this relevant?
Review
2001
Review
2001
Genasense (formerly known as G-3139), an antisense oligonucleotide specific for Bcl-2, is under development by Genta as an iv… (More)
Is this relevant?
Highly Cited
2000
Highly Cited
2000
BACKGROUND Chemoresistance of malignant melanoma has been linked to expression of the proto-oncogene BCL2. Antisense… (More)
Is this relevant?